Trial Profile
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Relamorelin (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan
- 03 Apr 2022 This trial has been completed in Hungary (Date of the global end of the trial : 30-Oct-2020), according to European Clinical Trials Database record.
- 31 Mar 2022 This trial has been completed in Bulgaria according to European Clinical Trials Database record.
- 28 Nov 2020 This trial has been completed in France (Date of the global end of the trial: 29 Oct 2020).